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Abstract
Background: The primary goal of therapy in patients with hypercholesterolemia and coronary heart disease (CHD) is 
reducing low-density lipoprotein cholesterol (LDL-C). This was a multicenter, randomized, double-blind, double-
dummy study in patients with type 2 diabetes mellitus (T2DM).
Methods: Adult patients with T2DM and CHD (N = 93) on a stable dose of simvastatin 20 mg with LDL-C ≥ 2.6 mmol/L 
(100 mg/dL) and ≤ 4.1 mmol/L (160 mg/dL) were randomized to ezetimibe 10 mg plus simvastatin 20 mg (EZ + simva 
10/20 mg) or simvastatin 40 mg for 6 weeks. Percent change in LDL-C, high-density lipoprotein cholesterol, and 
triglycerides was assessed.
Results: EZ + simva 10/20 mg produced a significantly greater change from treated baseline compared with 
simvastatin 40 mg in LDL-C (-32.2% vs -20.8%; p < 0.01) and total cholesterol (-20.6% vs -13.2%; p < 0.01). A greater 
proportion of patients achieved LDL-C < 2.6 mmol/L with EZ + simva 10/20 mg than with simvastatin 40 mg, but this 
was not statistically significant (78.4% vs 60%; odds ratio = 2.81; p = 0.052). Changes in high-density lipoprotein 
cholesterol and triglycerides were similar between treatments. Both treatments were generally well-tolerated.
Conclusions: These results demonstrate that EZ + simva 10/20 mg may provide a superior alternative for LDL-C 
lowering vs doubling the dose of simvastatin to 40 mg in hyperlipidemic patients with T2DM and CHD. In addition, the 
combination therapy may provide an alternative treatment for patients who require further LDL-C reduction than they 
can achieve with simvastatin 20 mg alone.
Background
Coronary heart disease (CHD) prevention through man-
agement of modifiable risk factors is of great importance
[1-3]. The International Task Force, working in coopera-
tion with the International Atherosclerosis Society [4],
identified patients with diabetes mellitus as very high risk
for CHD, and the National Cholesterol Education Pro-
gram Adult Treatment Panel (NCEP ATP) III [1] classi-
fied diabetes mellitus as a CHD risk equivalent. Type 2
diabetes mellitus (T2DM) has been shown to be associ-
ated with increased risk for CHD, which is the major
cause of mortality in patients with T2DM [5].
The consensus conference report from the American
Diabetes Association and American College of Cardiol-
ogy Foundation [6] suggests 3-hydroxy-3-methyl-glu-
taryl-CoA reductase inhibitors (statins) as initial therapy
for management of lipoprotein abnormalities in patients
with cardiometabolic risk, including T2DM. The recom-
mended low-density lipoprotein cholesterol (LDL-C)
treatment target for patients with T2DM is < 2.6 mmol/L
(< 100 mg/dL), with < 1.8 mmol/L (< 70 mg/dL) as an
optional therapeutic target in the US for patients with
T2DM and CHD [1,4,6]; and in Europe, the targets are
similar: < 2.5 mmol/L (< 97 mg/dL) with an optional goal
of < 2.0 mmol/L (< 77 mg/dL) [2]. A recent meta-analysis
of 14 randomized trials with statins in primary and sec-
ondary prevention in diabetes demonstrated the substan-
tial benefit of statins in reducing major cardiovascular
events independent of pre-treatment concentration of
LDL-C and similar to that observed in non-diabetic sub-
jects [7]. Despite evidence for the benefit of statin treat-
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ment, a considerable number of European patients are
not treated with lipid-lowering drugs [8], and specifically,
statins are appreciably underused in diabetic patients in
Italy [9]. In patients receiving treatment, a moderate dose
of statin may not be sufficient to reach recommended
LDL-C targets [10]. Significant LDL-C reductions have
been observed with more intensive therapy using higher
doses of statins, but not all patients tolerate high-dose
statins [11]. For some patients, the incidence of abnor-
malities in liver function or myopathy may increase in a
dose-dependant manner with this class of drugs [12]; and
even with a high dose, some patients still do not meet
treatment goals. Irrespective of dose, another important
aspect in determining the response to lipid-lowering
drugs is the balance between cholesterol synthesis and
absorption. Inter-individual variability of response has
been demonstrated both with statins, which reduce cho-
lesterol synthesis in the liver, and with ezetimibe, which
selectively blocks intestinal absorption of cholesterol by
binding the Niemann-Pick C1-Like 1 (NPC1L1) receptor
[13,14]. By targeting both mechanisms a greater reduc-
tion in LDL-C may be achieved. Statin therapy combined
with ezetimibe may provide effects on lipids that comple-
ment and surpass those of high-dose statins [15].
Ezetimibe monotherapy reduces LDL-C by ~18%, with
beneficial effects on total cholesterol, apolipoprotein B,
and triglycerides, and is generally well tolerated com-
pared with placebo [16]. When ezetimibe is co-adminis-
tered with a statin, complementary effects on the lipid
profile have been demonstrated, without significant
impact on the tolerability profile of either drug [16,17]. A
number of randomized studies have been published that
prospectively assessed the efficacy of ezetimibe plus sta-
tin specifically in diabetic patients with and without CHD
[18-21]. Ezetimibe/simvastatin (EZ + simva) combination
or ezetimibe added to statin in T2DM patients not at tar-
get with statin monotherapy consistently demonstrated
greater improvements in the lipid profile and a higher
proportion of patients achieving LDL-C targets com-
pared with doubling the dose of either simvastatin or
atorvastatin [18-21]. In order to extend and confirm these
results in a homogeneous population of patients attend-
ing outpatient diabetes clinics in Italy, this study com-
pared the LDL-C lowering efficacy and the safety and
tolerability of ezetimibe co-administered with simvasta-
tin 20 mg vs doubling the dose of simvastatin to 40 mg
after 6 weeks of treatment in patients diagnosed with
T2DM and CHD.
Methods
Study design
This was a multicenter, randomized, parallel-group, dou-
ble-blind, double-dummy placebo-controlled study con-
ducted at 22 sites in Italy from July 2005 to February
2007. The protocol (Protocol 04037) was reviewed and
approved by an Independent Ethics Committee at each
participating center, and patients provided written
informed consent prior to any study-related procedure
being started. The study was conducted under the provi-
sions of the Declaration of Helsinki and in accordance
with the International Conference on Harmonization
Consolidated Guideline on Good Clinical Practice.
Study population
Men and women aged 18-75 years with T2DM [with fast-
ing plasma glucose ≥ 7.0 mmol/L (126 mg/dL) and hemo-
globin (Hb) A1c ≤ 9.0%] of at least 12 months duration
and documented CHD (including stable angina with evi-
dence of ischemia on exercise testing, history of myocar-
dial infarction, percutaneous transluminal coronary
angioplasty, atherothrombotic cerebrovascular disease,
unstable angina or non-Q wave myocardial infarction), or
symptomatic peripheral vascular disease, who were tak-
ing a stable daily dose of simvastatin 20 mg for 6 weeks
with good compliance (80% of daily doses for the 6 weeks
prior to baseline visit) and had LDL-C concentration ≥
2.6 mmol/L (100 mg/dL) to ≤ 4.1 mmol/L (160 mg/dL)
were eligible for randomization. Patients were instructed
to follow a healthy lifestyle (cholesterol-lowering diet and
exercise) throughout the study. In addition, subjects were
required to have triglyceride concentrations < 3.99
mmol/L (350 mg/dL), liver transaminases [alanine amin-
otransferase (ALT) or aspartate aminotransferase (AST)]
and creatine phosphokinase (CK) < 50% above the upper
limit of normal (ULN) with no active liver disease, and
hematology, blood chemistry, and urinalysis within nor-
mal limits. Women of childbearing potential were
required to use effective birth control.
Patients were excluded if they had Class III or IV con-
gestive heart failure; uncontrolled cardiac arrhythmia;
recent (within 3 months of randomization) myocardial
infarction, acute coronary insufficiency, coronary artery
bypass surgery, or angioplasty, unstable or severe periph-
eral artery disease; newly diagnosed or unstable angina
pectoris, uncontrolled hypertension (treated or
untreated); uncontrolled endocrine or metabolic disease
known to influence serum lipids or lipoproteins;
impaired renal function (creatinine > 2.0 mg/dL) or neph-
rotic syndrome; or were taking any lipid-lowering agents,
fibrates, resins or niacins, or prescription and/or over-
the-counter-drugs with the potential for significant lipid
effects (other than study drug) or with potential drug
interactions with the statins.
Randomization and Blinding
Patients were randomized according to a computer-gen-
erated randomization schedule into two treatment
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mg + simvastatin 20 mg placebo or ezetimibe placebo +
simvastatin 20 mg for 6 weeks. All patients continued the
treatment with simvastatin 20 mg once daily using the
open label simvastatin 20 mg supplied. Because the
ezetimibe and simvastatin tablets were different in size,
shape and color, this study used a double-blind, double-
dummy design, i.e., ezetimibe and simvastatin tablets
were administered together with the alternative placebo.
Blinding was maintained until after study completion
and database closure. Patient compliance was assessed by
tablet count returned at the end of study. Compliance <
70% was considered a major protocol violation.
Efficacy measures
The primary efficacy measure was the percent change in
LDL-C from baseline to endpoint after 6 weeks of treat-
ment. Secondary efficacy measures were the percentage
of patients who reached LDL-C ≤ 2.6 mmol/L (100 mg/
dL) at endpoint and the percent change in total choles-
terol, high-density lipoprotein cholesterol (HDL-C), and
triglycerides from baseline to endpoint after 6 weeks of
treatment. The basic lipid panel assessment was con-
ducted at a central laboratory (Centro Diagnostico
EXACTA, Verona, Italy). LDL-C measurements were cal-
culated by the Friedewald equation [22].
Safety and tolerability
Adverse events were monitored at each visit and summa-
rized by system organ class and specific adverse experi-
ence term. Laboratory tests included complete blood
count, total protein, albumin, calcium, inorganic phos-
phorus, fasting plasma glucose, blood urea nitrogen, uric
acid, total bilirubin, alkaline phosphatase, ALT, AST,
gamma glutamyl transpeptidase, serum creatinine, thy-
roid stimulating hormone (baseline only), HbA1c,
sodium, potassium, chloride, CK; and urinalysis. The
analysis of laboratory parameters was conducted at a cen-
tal laboratory (Centro Diagnostico EXACTA, Verona,
Italy).
Statistics
Primary and secondary endpoints were assessed in the
intent-to-treat (ITT) population, which included all sub-
jects who were randomized, had taken at least one dose
of study drug, and had at least one measurement at base-
line and after the start of treatment. The primary efficacy
endpoint was assessed using the analysis of variance
(ANOVA) model, which included terms for treatment
effect. Estimates via least-squares means between mean
differences and 95% confidence intervals were provided.
Secondary efficacy parameters and laboratory variables
were analyzed using ANOVA with treatment as a group-
ing factor. Multiple comparisons within and between
treatments were performed. A stepwise logistic regres-
sion model with terms for treatment, baseline LDL-C,
age, and HbA1c was used to predict the probability of
achieving LDL-C < 2.6 mmol/L (100 mg/dL). The safety
population included all randomized patients who took at
least one dose of study drug. The incidence of adverse
events was compared between treatments using the
Fisher exact test with Yates correction if applicable.
Results
The flow of patients through the study is shown in Figure
1. Of the 162 patients screened, 51 were randomized to
the simvastatin group and 42 were randomized to the EZ
+ simva group. A total number of 6 patients withdrew
from the study after randomization: 4 in the EZ + simva
group and 2 in the simvastatin group. Reasons were
adverse events in 1 patient and poor compliance in 3 in
the EZ + simva group, and adverse events in the 2
patients in the simvastatin group. However, the 3 patients
that discontinued the study due to adverse events under-
went the final visit and were included in the ITT popula-
tion. There were 3 patients with no evidence of intake of
study drug, and these were excluded from the safety pop-
ulation.
Baseline characteristics are shown in Table 1. The mean
age (± standard deviation) was 65 (± 6.5) years in the EZ +
simva group and 64 (± 6.1) years in the simvastatin group.
All patients were Caucasian and most patients were male
(57% in the EZ + simva group and 76% in the simvastatin
group; p = 0.078). The two treatment groups were similar
with regard to demographic data, medical history, cardio-
vascular risk factors, and baseline values of all efficacy
and safety parameters except AST (p = 0.001), ALT (p =
0.002), and CK (p = 0.002) mean values, which were sig-
nificantly higher in the simvastatin group compared with
the EZ + simva group. The mean LDL-C in the ITT popu-
lation was 3.28 mmol/L (126.6 mg/dL) in the EZ + simva
group and 3.24 mmol/L (125.2 mg/dL) in the simvastatin
group. Table 1 shows the types of CHD reported at base-
line. Ischemic heart disease was the most common form
of CHD at baseline, with 22 (60%) patients in the EZ +
simva group and 27 (54%) patients in the simvastatin
group.
Compared with doubling the dose of simvastatin to 40
mg (Figure 2), treatment with EZ + simva 10/20 mg
resulted in a significantly greater mean reduction in LDL-
C after 6 weeks (-32.2% vs -20.8%; p < 0.01). In addition,
the proportion of patients achieving the recommended
LDL-C target < 2.6 mmol/L (< 100 mg/dL) at 6 weeks was
numerically greater with EZ + simva 10/20 mg (78%)
compared with simvastatin 40 mg treatment (60%),
although this was not statistically significant (odds ratio =
2.81; 95% confidence interval: 0.99, 7.97, p = 0.052). The
estimated treatment effect was dependent on baseline
LDL-C value (p = 0.010), but not age or HbA1c level at
baseline. The percent reduction in total cholesterol (Fig-Bardini et al. Cardiovascular Diabetology 2010, 9:20
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ure 3) was significantly greater after 6 weeks of EZ +
simva 10/20 mg treatment compared with doubling the
dose of simvastatin to 40 mg (-20.6% vs -13.2%; p < 0.01).
Changes in HDL-C (0.85% EZ + simva vs 0.80% simvasta-
tin) and triglycerides (-8.5% EZ + simva vs -1.8% simvas-
tatin) were similar between treatment groups (Figure 3).
A summary of safety results is shown in Table 2. The
proportion of patients who reported adverse events was
similar between treatment groups (p = 0.507), with few
discontinuations due to adverse events (only 1 patient in
the EZ + simva group and 2 in the simvastatin group). No
differences between groups were observed in the number
and rate of drug-related events, which were reported in
7.5% of patients in the EZ + simva group and in 6.0% of
patients in the simvastatin group (p = 1.000). One serious
adverse event was reported (bone fracture) that was con-
sidered non-drug-related. There were no reports of
increased ALT or AST ≥ 3 × ULN or CK ≥ 5 × ULN, and
no deaths occurred at any time during the study in either
treatment group. There were no clinically significant
changes in plasma glucose or HbA1c in either group.
Discussion
These results demonstrated that ezetimibe 10 mg in com-
bination with ongoing simvastatin 20 mg produced sig-
nificantly greater LDL-C and total cholesterol reductions
compared with doubling the dose of simvastatin to 40 mg
in patients with primary hypercholesterolemia, T2DM,
and CHD not at the LDL-C target < 2.6 mmol/L (< 100
mg/dL) with simvastatin 20 mg/day for at least 6 weeks.
In addition, more patients in the combination EZ + simva
10/20 mg group achieved the target LDL-C goal as
defined by the NCEP ATP III guidelines than in the sim-
vastatin 40 mg group, although this was not statistically
significant. The treatment effect was in favor of EZ +
simva with nearly a threefold odds of reaching the LDL-C
< 2.6 mmol/L (< 100 mg/dL) vs doubling the dose of sim-
vastatin. The probability of reaching this target was inde-
Figure 1 Flow of patients through the study. *No evidence of intake of study drug; †Patients that discontinued the study due to adverse events 
underwent the final visit and were included in the ITT population.Bardini et al. Cardiovascular Diabetology 2010, 9:20
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pendent of age and HbA1c level at baseline within the
range of values of this population. Changes in HDL-C and
triglycerides were similar between treatment groups, and
these changes were consistent with results of previous tri-
als comparing EZ + simva combination vs statin mono-
therapy in T2DM patients [19-21]. Treatment with EZ +
simva 10/20 mg or simvastatin 40 mg was generally well-
tolerated.
The results of this study were consistent with previous
studies of similar design and duration conducted in the
general population of patients with hypercholesterolemia
and CHD [23,24]. They are also generally consistent in
patients with T2DM [18-21,25]. In clinical studies of
patients with T2DM not at the recommended LDL-C tar-
get < 2.6 mmol/L (< 100 mg/dL) with a previous statin
treatment, EZ + simva was consistently superior to dou-
bling the ongoing statin dose in reducing the LDL-C val-
ues and in getting patients to the LDL-C target [18,20,21].
Of note, in the present study the reduction in LDL-C that
occurred with doubling the dose of simvastatin was
higher than that observed in many previous studies of
similar design, which showed reductions of < 10%
[18,20,21]. These effects were also observed in a larger
study with similar design to the present one comparing
EZ + simva 10/20 mg with atorvastatin 20 mg in hyperc-
holesterolemic CHD patients without diabetes [23]. The
Table 1: Baseline patient characteristics
EZ + Simva 10/20 mg 
(N = 37)
Simva 40 mg 
(N = 50)
Between treatment 
difference
Demographics
Age, mean years (SD) 65 (6.5) 64 (6.1) p = 0.204
Females, n (%) 16 (43.2) 12 (24.0) p = 0.078
Body mass index, kg/m2, mean (SD) 28.9 (4.1) 28.4 (3.6) p = 0.584
Hypertension, n (%) 30 (81.1) 32 (62.0) p = 0.090
Baseline lab values, mean (SD)
Low-density lipoprotein cholesterol, mmol/L 3.3 (0.5) 3.2 (0.5) p = 0.413
Total cholesterol, mmol/L 5.2 (0.6) 5.1 (0.6) p = 0.335
High-density lipoprotein cholesterol, mmol/L 1.2 (0.3) 1.1 (0.3) p = 0.202
Triglycerides, mmol/L 1.6 (0.7) 1.6 (0.7) p = 0.933
Fasting plasma glucose, mmol/L 10.2 (2.7) 10.0 (2.9) p = 0.717
Hemoglobin A1c 7.5 (0.7) 7.4 (0.8) p = 0.539
Aspartate aminotransferase, U/L 16.9 (3.4) 20.2 (5.1) p = 0.001
Alanine aminotransferase, U/L 20.8 (7.1) 27.6 (11.4) p = 0.002
Creatine kinase, U/L 80.4 (35.5) 107.5 (47.3) p = 0.002
Prevalence of cardiovascular diseases, n (%)
Cerebrovascular disease 3 (8.1) 5 (10.0) p = 1.000
Peripheral vascular disease 7 (18.9) 11 (22.0) p = 0.999
Ischemic heart disease 22 (59.5) 27 (54.0) p = 0.666
Cerebrovascular disease + PAD 1 (2.7) 2 (4.0) p = 1.000
Cerebrovascular disease + ischemic heart 
disease
0 (0.0) 0 (0.0) --
PAD + ischemic heart disease 3 (8.1) 4 (8.0) p = 1.000
Cerebrovascular disease + PAD + ischemic 
heart disease
1 (2.7) 1 (2.0) p = 1.000
N, number in full analysis set population; SD, standard deviation; n, number; PAD, peripheral arterial disease Bardini et al. Cardiovascular Diabetology 2010, 9:20
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reasons for the inconsistency observed in the response to
doubling statin dose are not fully understood. We specu-
late that this could be due to study effect or to good com-
pliance. On the other hand, most studies and post hoc
analyses did not include a comparison of goal attainment
between patient groups, nor an analysis of factors that
predict the odds of achieving goal. One report did show
that more patients in the diabetes group achieved the rec-
ommended LDL-C goal compared with non-diabetics
(83.6% versus 67.2%), although this result was not statisti-
cally significant after adjusting for differences in baseline
LDL-C levels [26]. In addition, a significant interaction
for LDL-C lowering was observed in a preliminary report
of a post hoc analysis of patients in the IN-CROSS study,
indicating larger between-group reductions in patients
with T2DM versus those without T2DM [27]. Further
study in larger populations that directly compare the effi-
cacy of combination therapy with statin monotherapy in
diabetics vs non-diabetics is warranted.
EZ + simva combination therapy at the usual recom-
mended starting dose of 10/20 mg, and at the next higher
dose of 10/40 mg vs the recommended usual starting
dose and next highest dose of atorvastatin (10, 20, and 40
mg, respectively), was consistently superior to statin
monotherapy in reducing LDL-C levels and attaining
LDL-C levels < 1.8 mmol/L (< 70 mg/dL) in T2DM
patients [19-21]. The results of the current trial confirm
previous findings in patients with T2DM and extend
them to include a population of patients treated in outpa-
tient diabetes clinics.
Recent investigations on the changes in the cholesterol
homeostasis in patients with CHD and/or diabetes seem
to support the concept that a complementary approach
targeting both the synthesis and the intestinal absorption
of cholesterol can improve the lipid profile of patients
who show a poor response to statin monotherapy better
than high dose/high potency statin monotherapy [28-30].
It has been suggested that reducing cholesterol absorp-
tion using ezetimibe treatment combined with a statin,
which lowers hepatic cholesterol synthesis, may be a
practical approach to intensive lipid management and
goal achievement compared with treatments that reduce
synthesis alone [28-30]. This may be of particular rele-
vance in T2DM patients, who have been shown to have
higher levels of NPC1L1 mRNA and increased intestinal
absorption of biliary and newly synthesized cholesterol.
One mechanism by which NPC1L1 may be increased in
T2DM patients is through elevated glucose concentra-
tions [31]. Cultured Caco-2/15 cells exposed to high glu-
cose levels displayed a significant increase in protein
expression of NPC1L1, and when ezetimibe was added to
the culture medium, the action of the glucose was
reduced [31]. In addition to differences in NPC1L1 pro-
tein expression, a disturbance in the ATP binding cassette
(ABC) proteins G5 and G8, which regulate cholesterol
homeostasis, may play a role in the dyslipidemia of dia-
betic patients. Specifically, compared with non-diabetics,
diabetic patients have decreased mRNA expression of
both ABCG5 and G8, leading to increased levels of sitos-
terol and cholesterol in chylomicrons [32]. Taken
together, these results suggest that both increased
NPC1L1 and lower ABCG5 and G8 may lead to an
increase in cholesterol absorption in diabetic patients,
and targeting both the synthesis and the intestinal
absorption of cholesterol in the treatment of diabetic dys-
lipidemia may be prudent. This view is further supported
b y  t h e  f i n d i n g s  o b t a i n e d  i n  h i g h  c a r d i o v a s c u l a r  r i s k
patients, which demonstrated between-group LDL-C
Figure 2 Mean% change from baseline in LDL-C after 6 weeks of 
treatment.
Figure 3 Percent change in total cholesterol, HDL-C and triglycer-
ides after 6 weeks of treatment.Bardini et al. Cardiovascular Diabetology 2010, 9:20
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reductions in favor of EZ + simva vs rosuvastatin 10 mg
in patients who were not at LDL-C target prior to switch
and suggested that there was a high proportion of poor
responders to statin therapy in this group [29]. Additional
clinical trials to assess cardiovascular outcomes with
ezetimibe added to statin therapy are ongoing.
In the present study, both treatment regimens had sim-
ilar safety and tolerability profiles during the study
period. Despite higher baseline laboratory values in the
simvastatin group, there were no reports of increased
ALT or AST ≥ 3 × ULN nor CK ≥ 5 × ULN in this treat-
ment group during the study, nor were there reports of
increases in ALT, AST, or CK in the EZ + simva 10/20 mg
group. Accordingly, neither the addition of ezetimibe to
simvastatin 20 mg nor doubling the dose of simvastatin to
40 mg resulted in reports of myopathy or rhabdomyoly-
sis. These results are consistent with expectations for
these drugs at the doses given and with previous trials in
this patient population [17-19,25,33]. Although the inci-
dence of serious adverse events was low, this study was
relatively small and not powered nor of sufficient dura-
tion to assess the prevalence of rare adverse events. Clini-
cal trial registration: NCT00423488
Conclusion
In conclusion, the results of this study demonstrate that
co-administration of ezetimibe with simvastatin 20 mg
may provide a superior alternative for LDL-C lowering
compared with doubling the dose of simvastatin to 40 mg
in hyperlipidemic patients with T2DM and CHD. In addi-
tion, the combination therapy was generally well toler-
ated, providing an alternative treatment for patients who
require further LDL-C reduction than with simvastatin
20 mg alone.
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ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; CK, creatine kinase.
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